Amicus Therapeutics, Inc. (FOLD) CEO John F. Crowley Sells 71,735 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 71,735 shares of the stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total value of $1,058,091.25. Following the sale, the chief executive officer now owns 380,723 shares in the company, valued at approximately $5,615,664.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Amicus Therapeutics, Inc. (FOLD) traded down 2.03% on Friday, hitting $14.02. 1,252,261 shares of the stock traded hands. The stock’s market cap is $2.31 billion. The company’s 50 day moving average price is $14.45 and its 200-day moving average price is $11.05. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter in the previous year, the company earned ($0.40) EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.truebluetribune.com/2017/10/20/amicus-therapeutics-inc-fold-ceo-john-f-crowley-sells-71735-shares.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of Amicus Therapeutics by 3.4% during the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after buying an additional 705,153 shares in the last quarter. Redmile Group LLC lifted its stake in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares in the last quarter. Palo Alto Investors LLC lifted its stake in shares of Amicus Therapeutics by 0.7% during the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after buying an additional 57,800 shares in the last quarter. Finally, Janus Capital Management LLC lifted its stake in shares of Amicus Therapeutics by 3.6% during the 1st quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after buying an additional 244,906 shares in the last quarter.

Several research firms have issued reports on FOLD. Zacks Investment Research downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 6th. Chardan Capital restated a “buy” rating and set a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Robert W. Baird restated an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Finally, J P Morgan Chase & Co restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and an average target price of $17.81.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply